Best of ASTRO® 2024: Hematology Updates – Dr. Tarek Hijal
OR
Chair
Dr. Paris-Ann Ingledew
Dr. Joanne Alfieri
Speaker
Dr. Tarek Hijal
Studies/trials discussed:
- Phase I Trial of ‘Re-Priming’ Radiation Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
- Consolidative Radiotherapy for Residual PET-Avid Disease on Day +30 Post CAR T-Cell Therapy in Non-Hodgkin Lymphoma
- Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study
- Management and Outcomes of Hodgkin Lymphoma Patients Who Achieve Partial Metabolic Response on PET Scans Post-Chemotherapy
- Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation
- Phase II Multi-Institutional Study of a Low-Dose (4 Gy) Palliative Response-Adapted Radiotherapy Regimen for Symptomatic Bone Metastases from Multiple Myeloma
